Michael Jahnke, a partner with Loeb & Loeb, discusses revisions, likely to take effect in the first quarter of 2013, which will require more pharma patent licenses to be reported under the Hart-Scott-Rodino Act and will give valuation of those licenses greater importance.
FTC, DOJ to Heighten Reporting Requirements on Patents
New York Law Journal
January 7, 2013
This article requires premium access
This article requires premium access to The New York Law Journal. Please sign in or subscribe to read the full text.